Open AccessPopulation Pharmacokinetic Analysis of Asunaprevir in Subjects with Hepatitis C Virus Infection
Author(s) -
Li Zhu,
Hanbin Li,
Phyllis Chan,
Timothy Eley,
Yash Gandhi,
Marc Bifano,
Mayu Osawa,
Toshinori Ueno,
Eric Hughes,
Malaz AbuTarif,
Richard Bertz,
Tushar Garimella
Publication year - 2018
Publication title -
infectious diseases and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.399
H-Index - 28
eISSN - 2193-8229
pISSN - 2193-6382
DOI - 10.1007/s40121-018-0197-y
Subject(s) - medicine , hepatitis c virus , population , pharmacokinetics , virology , hepatitis c , virus , environmental health
Asunaprevir (ASV) is a potent, pangenotypic, twice-daily hepatitis C virus (HCV) NS3 inhibitor indicated for the treatment of chronic HCV infection.